Effects of angiotensin-converting enzyme inhibitor, angiotensin II type I receptor blocker and their combination on postinfarcted ventricular remodeling in rats

被引:12
|
作者
Zhang, RY
Wang, LF [1 ]
Zhang, L
Meng, XN
Li, SJ
Wang, WR
机构
[1] Harbin Med Coll, Clin Hosp 1, Dept Cardiol, Harbin 150001, Peoples R China
[2] Harbin Med Coll, Clin Hosp 1, Dept Pathol, Harbin 150001, Peoples R China
关键词
Smad; ventricular remodeling; angiotensin converting enzyme inhibitor; angiotensin II type I receptor blocker;
D O I
10.1097/00029330-200604020-00006
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Transforming growth factor (TGF) beta(1)-Smads signal plays an important role in cardiac remodeling following myocardial infarction (MI). In addition, both angiotensin converting enzyme inhibitor (ACEI) and angiotensin II type I receptor blocker (ARB) can effectively prevent left ventricular remodeling. The current study focused on whether the combination of ACEI and ARB is more beneficial for preventing ventricular remodeling and whether Smad proteins mediate this beneficial effect. Methods MI was induced by ligating the left anterior descending coronary artery in rats. Twenty-four hours after ligation, the survived rats were randomly divided into five groups and treated for 8 weeks: placebo group, ACEI group (benazepril 10 mg (.) kg(-1) (.) d(-1)), ARB group (irbesartan 50 mg (.) kg-(1 .) d(-1)), ACEI + ARB group (benazepril 10 mg (.) kg (.) d(-1) + irbesartan 50 mg (.) kg (.) d(-1)) and control group (sham-operated rats). After 8 weeks, we examined the following indexes: the ratio of ventricular weight to body weight,(VW/BW), left ventricular end diastolic dimension (LVDd), ejection fraction (EF), fractional shortening (FS), ratio of E-wave to A-wave velocity, collagen of noninfarcted zone, the mRNA expression of TGF beta(1), Smad 2, and Smad 3 by RT-PCR in noninfarcted zone, the protein expression of Smad 2 and Smad 3 in noninfarcted zone by Western blot. Results VW/BW significantly increased in the placebo groups compared with that in the control group (P < 0.01). This increase was limited in ACEI, ARB, and combined groups (P < 0.01 compared with placebo group). There was no significant difference among the three actively treated groups. Collagen was increased in placebo group (5.68 +/- 0.5)% compared with that in control group (P < 0.01). ACEI, ARB and combined treatment attenuated this increase of collagen [(4.3 +/- 0.5)%, (3.5 +/- 0.5)%, (3.2 +/- 0.4)%] in comparison with that in placebo group (P < 0.01 respectively). Combined treatment showed more significant effect on collagen deposition. EF and FS significantly decreased, LVDd and E/A significantly increased in placebo group compared with that in control group (P < 0.01 respectively). ACEI, ARB and combined treatment ameliorated these indexes (P < 0.01 compared with placebo group). The mRNA expression of TGF beta(1), Smad 2, and Smad 3 (0.700 +/- 0.045, 0.959 +/- 0.037 and 0.850 +/- 0.051) increased in placebo group compared with that in control group (P < 0.01). ACEI, ARB and combined treatment normalized the increase (P < 0.01). Furthermore, ARB and combined treatment proved to be more effective in decreasing TGF beta(1) and Smad mRNA expression than ACEI treatment (P < 0.01). The expression of Smad 2 and Smad 3 protein increased in placebo group compared with that in control group (P < 0.01). ACEI, ARB and combined treatment normalized the increase (P < 0.01). Furthermore, ARB and combined treatment proved to be more effective than ACEI alone (P < 0.01). Conclusions TGF beta(1)-Smads signal activation is correlated with ventricular remodeling following MI. ACEI and ARB treatment prevents ventricular remodeling by inhibiting expression of Smad 2 and Smad 3.. ARB and combined treatment are more effective than ACEI alone.
引用
收藏
页码:649 / 655
页数:7
相关论文
共 50 条
  • [31] Uncritical Acceptance of Combination Treatment of Angiotensin II Receptor Blocker and Angiotensin-Converting Enzyme Inhibitor in Nondiabetic Renal Disease Trial Results
    Griffin, Karen A.
    Bidani, Anil K.
    HYPERTENSION, 2009, 53 (01) : E3 - E3
  • [32] Safety and tolerability of angiotensin-converting enzyme inhibitor versus the combination of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker in patients with left ventricular dysfunction: A systematic review and meta-analysis of Randomized controlled trials
    Lakhdar, Rachid
    Al-Mallah, Mouaz H.
    Lanfear, David E.
    JOURNAL OF CARDIAC FAILURE, 2008, 14 (03) : 181 - 188
  • [33] Angiotensin-converting Enzyme Inhibitor And Angiotensin II Receptor Blocker-Induced Angioedema: Overuse of Ineffective Treatment
    Nasir, M.
    Sharma, G.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2011, 127 (02) : AB105 - AB105
  • [34] Quantifying Proximal Collecting Tubule Deficiency in Angiotensin-Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker Fetopathy
    Saunders, Jessica
    Callejas Salgado, Allison Marie
    Ting, Joseph Y.
    Mammen, Cherry
    Terry, Jefferson
    Bush, Jonathan W.
    PEDIATRIC AND DEVELOPMENTAL PATHOLOGY, 2021, 24 (05) : 438 - 444
  • [35] Angiotensin converting enzyme inhibitor or angiotensin II receptor blocker for the prevention of type 2 diabetes mellitus?
    Chen, Ching-Chu
    Chiang, An-Na
    Hsieh, Min-Huang
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2010, 90 (02) : E25 - E26
  • [36] An angiotensin-converting enzyme inhibitor, not an angiotensin II type-1 receptor blocker, prevents β-aminopropionitrile monofumarate-induced aortic dissection in rats
    Nagashima, H
    Uto, K
    Sakomura, Y
    Aoka, Y
    Sakuta, A
    Aomi, S
    Hagiwara, N
    Kawana, M
    Kasanuki, H
    JOURNAL OF VASCULAR SURGERY, 2002, 36 (04) : 818 - 823
  • [37] Effects of an angiotensin-converting enzyme inhibitor and a β-blocker on cerebral arteriolar dilatation in hypertensive rats
    Chillon, JM
    Baumbach, GL
    HYPERTENSION, 2001, 37 (06) : 1388 - 1393
  • [38] Is Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Combination Therapy Better Than Monotherapy and Safe in Patients With CKD?
    Berns, Jeffrey S.
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2009, 53 (02) : 192 - 196
  • [39] Acute effect of angiotensin II receptor blocker and angiotensin converting enzyme inhibitor on baroreflex
    Shimizu, M
    Mochizuki, T
    Sasaoka, T
    Kurosawa, T
    Kurokawa, S
    Tsuyusaki, T
    Izumi, T
    JOURNAL OF HYPERTENSION, 2000, 18 : S232 - S232
  • [40] Effect of angiotensin converting enzyme inhibitor and angiotensin II receptor blocker on the patients with sepsis
    Lee, Hyun Woo
    Suh, Jae Kyung
    Jang, Eunjin
    Lee, Sang-Min
    KOREAN JOURNAL OF INTERNAL MEDICINE, 2021, 36 (02): : 371 - 381